Status:
COMPLETED
Effectiveness and Safety of YVOIRE Y-Solution 540
Lead Sponsor:
LG Chem
Conditions:
Wrinkles in the Nasolabial Folds
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
To Evaluate the Effectiveness and Safety of YVOIRE Y-Solution 540 versus YVOIRE volume plus in Nasolabial Folds Injection
Eligibility Criteria
Inclusion
- 3 (moderate) or 4 (severe) on the 5-graded WSRS
- who sign the written informed consent form
Exclusion
- who have received permanent facial implants
- who have received semi-permanent fillers
- who have undergone temporary dermal filler treatment within 12 months
- who have undergone facial tissue augmentation with fat injections, botulinum toxin injections, mesotherapy, or cosmetic procedures within 6 months
- who have a history of anaphylaxis or allergy to lidocaine, hyaluronic acid (HA) products, or streptococcal protein
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 14 2024
Estimated Enrollment :
394 Patients enrolled
Trial Details
Trial ID
NCT04855188
Start Date
July 1 2021
End Date
July 14 2024
Last Update
December 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China